These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18299665)

  • 1. Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.
    Hann HW
    Minerva Gastroenterol Dietol; 2008 Mar; 54(1):19-30. PubMed ID: 18299665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
    Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR; Lee HJ; Kim TN; Lee KS
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H; Lok AS
    Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Kim BK; Han KH; Ahn SH
    Oncology; 2011; 81 Suppl 1():41-9. PubMed ID: 22212935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF
    Semin Liver Dis; 2005; 25 Suppl 1():40-7. PubMed ID: 16103980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatocellular carcinoma and its recurrence with anti-hepatitis B viral therapy.
    Halegoua-De Marzio D; Hann HW
    Minerva Gastroenterol Dietol; 2014 Sep; 60(3):191-200. PubMed ID: 25000955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress and new trends in the treatment of hepatitis B.
    Alberti A; Brunetto MR; Colombo M; Craxì A
    J Med Virol; 2002 Jul; 67(3):458-62. PubMed ID: 12116046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E; Bergk A; Berg T
    Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telbivudine for the management of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
    Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
    J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.